Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVACURE-2
2025-522659-24-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin and GC101 TIL + pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Leiden University Medical Center. Primary endpoint: Immunotherapy-related grade III/IV NCI-CTC toxicity. Planned start Sep 2026; status: authorised.
02
Drugs
aldesleukinGC101 TIL + pembrolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2025-522659-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522659-24-00.